Research Topics
| H A WakeleeSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Aflibercept in lung cancerJoel W Neal
Stanford University Stanford Cancer Institute, Department of Medicine Oncology, Stanford, CA, USA
Expert Opin Biol Ther 13:115-20. 2013..There remains hope that identification of biomarkers of response will one day help select patients most likely to benefit from antiangiogenesis therapy...
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501Heather A Wakelee
Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
J Thorac Oncol 7:1574-82. 2012..Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers. This phase-II study in heavily pretreated non-small-cell lung cancer (NSCLC) patients (≥ 2 prior therapies) used a randomized discontinuation design...- A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumorsSukhmani K Padda
Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
Cancer Chemother Pharmacol 69:1013-20. 2012..Erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, has activity in solid tumors. Based on the promising combination of EGFR inhibitors and anti-angiogenic agents, this phase I trial was initiated... - Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumabH A Wakelee
Department of Medicine Division of Oncology, Stanford University, Stanford, CA, USA
Lung Cancer 76:410-5. 2012..The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex... - A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)Heather A Wakelee
Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
Cancer Chemother Pharmacol 69:815-24. 2012..This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination... 
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee
Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
J Thorac Oncol 1:441-6. 2006..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy...- Novel approaches for the treatment of small cell lung cancerHeather Wakelee
Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Hematol Oncol Clin North Am 18:499-518. 2004 - Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancerHeather Wakelee
Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford, California 94305 5826, USA
Clin Lung Cancer 9:9-15. 2008..Ongoing trials within the cooperative groups continue to drive steady improvement in the treatment of lung cancer and offer great promise for the future... - Antibodies to vascular endothelial growth factor in non-small cell lung cancerHeather Wakelee
Department of Medicine, Division of Oncology, Stanford University, Stanford Cancer Center, Stanford, California 94305 5826, USA
J Thorac Oncol 3:S113-8. 2008..Exploration of the safety and efficacy of the drug in combination with other chemotherapeutics and targeted agents, and in previously excluded patient populations such as those with brain metastases, is also ongoing... - Adjuvant chemotherapy for resected non-small cell lung cancerHeather Wakelee
Department of Medicine Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
Semin Thorac Cardiovasc Surg 20:198-203. 2008..Other studies looking at tumor gene and protein expression will lead us toward better identification of patients most likely to benefit from therapy... - Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancerHeather Wakelee
Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA 94305, USA
Clin Lung Cancer 9:346-51. 2008..Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer... - Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumorsH A Wakelee
Department of Medicine Oncology, Stanford University, Stanford, CA 94305 5826, USA
Ann Oncol 21:376-81. 2010..Materials and methods: This phase 1, dose escalation study assessed the safety, tolerability, pharmacokinetics (PKs) and immunogenicity of lexatumumab administered i.v. every 14 days in patients with advanced solid tumors... - Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer CongressHeather Wakelee
Department of Medicine, Division of Oncology, Stanford University Cancer Center, Stanford, CA 94305 5826, USA
Clin Lung Cancer 10:395-404. 2009.... - The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancerHeather A Wakelee
Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
Cancer Chemother Pharmacol 69:563-71. 2012..This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents... - Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I diseaseHeather Wakelee
Oncology, Stanford University, 875 Blake Wilbur Drive, Room 2233, Stanford, California 94305 5826, USA
Oncologist 12:331-7. 2007..Strategies such as inhibition of angiogenesis pathways and the epidermal growth factor receptor are under exploration... - Lung cancer incidence in never smokersHeather A Wakelee
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
J Clin Oncol 25:472-8. 2007..However, data on this topic, particularly lung cancer incidence rates in never smokers, are limited... - Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology GroupHeather A Wakelee
Stanford Clinical Cancer Center, 875 Blake Wilbur Drive, Room 2231, Stanford, CA 94305 5826, USA
Lung Cancer 48:389-97. 2005..The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT... - Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990Heather A Wakelee
Department of Medicine, Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
Cancer 106:2208-17. 2006.... - Second- and third-line treatments in non-small cell lung cancerAtul Kumar
Stanford Cancer Center, Stanford, CA 94305, USA
Curr Treat Options Oncol 7:37-49. 2006.... - Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitorsHeather A Wakelee
Oncology Division, Stanford University School of Medicine, CA, USA
Clin Lung Cancer 7:S6-12. 2005..Gimatecan and other novel camptothecins have superior preclinical activity and promising phase I/II data in NSCLC and SCLC... - Docetaxel in advanced non-small cell lung cancerHeather Wakelee
Stanford University School of Medicine, Stanford University Cancer Center, 875 Blake Wilbur Dr, Stanford, CA 94305 5826, USA
Expert Rev Anticancer Ther 5:13-24. 2005..This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC... - A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancerHeather Wakelee
Stanford Clinical Cancer Center, Stanford, CA 94305-5826, USA
Invest New Drugs 23:241-2. 2005 - Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup TrialHeather A Wakelee
Stanford Cancer Center, CA 94305 5826, USA
Clin Lung Cancer 8:18-21. 2006..Because of the recent update, this trial will now limit patients with stage IB disease to those with larger tumors (>or= 4 cm) and will likely include only cisplatin-based regimens... - Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitorsElwyn Cabebe
Stanford University, Stanford Cancer Center, Stanford 94305 5826, USA
Curr Treat Options Oncol 8:15-27. 2007..We can hope that further improvements in survival will follow... - Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumorsQuynh Thu Le
Department of Radiation Oncology, Stanford University, Stanford, California, USA
J Thorac Oncol 1:802-9. 2006..The purpose of this study was to report initial results of a phase I study using single-fraction stereotactic radiotherapy (RT) in patients with inoperable lung tumors... - Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a reviewChristelle Clément-Duchêne
Division of Medical Oncology, Stanford Clinical Cancer Center, Stanford, California 94305 5826, USA
J Thorac Oncol 5:129-39. 2010..This article will review these new targeted antiangiogenic and antivascular agents with a focus on their use as lung cancer therapeutics... - Sunitinib: a newly approved small-molecule inhibitor of angiogenesisElwyn Cabebe
Division of Medical Oncology, Stanford University, Stanford, California 94305, USA
Drugs Today (Barc) 42:387-98. 2006.... - An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancersQuynh Thu Le
Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5847, USA
Clin Cancer Res 12:1507-14. 2006..To directly assess tumor oxygenation in resectable non-small cell lung cancers (NSCLC) and to correlate tumor pO2 and the selected gene and protein expression to treatment outcomes... - Optimizing first-line treatment options for patients with advanced NSCLCHeather Wakelee
Stanford University, Stanford, California, USA
Oncologist 10:1-10. 2005..Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC... - Pemetrexed disodium for the treatment of NSCLC: an updateJerry Y Hsu
Division of Medical Oncology, Stanford University, Stanford, California 94305 5826, USA
Drugs Today (Barc) 44:669-78. 2008..Pemetrexed is currently being tested in clinical trials as part of second-line combination, first-line, adjuvant and maintenance therapies... - Complications of ablative therapies in lung cancerSukhmani Padda
Department of Medicine, Stanford University, Stanford, CA, USA
Clin Lung Cancer 9:122-6. 2008..These cases highlight the caution that should still be observed when recommending lung ablation strategies and the importance of selecting appropriate patients... - AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancerJoel Neal
Stanford University Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
Curr Opin Mol Ther 12:487-95. 2010..If safe and effective, AMG-386 could be an exciting addition to other antiangiogenic therapies in solid tumors... - Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
J Thorac Oncol 3:S107-12. 2008..A CME activity based on this summary is also available at www.informedicalcme.com/cme... - Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic responseJessica S Donington
Department of Cardiothoracic Surgery, Stanford University School of Medicine, CA 94303, USA
Clin Lung Cancer 8:22-9. 2006..Several phase II trials with small-molecule inhibitors of Src are under way or have been initiated in lung cancer and in other malignancies, as discussed herein... - Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancerHeather A Wakelee
Oncology Division, Stanford University School of Medicine, CA, USA
Clin Lung Cancer 7:S31-8. 2005..We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer... - Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancerTimothy Kuo
Oncology Division, Department of Medicine, Stanford University School of Medicine, 269 Campus Dr, CCSR 1105, Stanford, CA 94305-5151, USA
J Clin Oncol 23:5613-9. 2005..CONCLUSION: IFOX is an active regimen in patients with previously treated metastatic colorectal adenocarcinoma, demonstrating higher response rates than those reported with FOLFOX-4 alone in a similar patient population... - Sex differences in lung-cancer susceptibility: a smoke screen?Heather A Wakelee
Lancet Oncol 9:609-10. 2008 - A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinomaMillie S Roy
Department of Medicine, Stanford University School of Medicine, CA, USA
Clin Lung Cancer 8:146-8. 2006.... - Lung cancer presenting with amegakaryocytic thrombocytopeniaWesley H Witteles
Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
J Clin Oncol 26:1171-4. 2008 - Metabolic tumor burden predicts for disease progression and death in lung cancerPercy Lee
Department of Radiation Oncology, Stanford University, Stanford, CA 94305 5847, USA
Int J Radiat Oncol Biol Phys 69:328-33. 2007..However, stage may be simply a surrogate for underlying tumor burden. Our purpose was to assess the prognostic value of tumor burden measured by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging...